NCT00653250View on ClinicalTrials.gov

Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 31, 2000

Primary Completion Date

March 31, 2006

Study Completion Date

January 31, 2008

Conditions
Lung Cancer
Interventions
DRUG

celecoxib

400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)

PROCEDURE

biopsy

in patients with newly diagnosed NSCLC, a pretreatment excision of a small amount of tumor tissue

PROCEDURE

therapeutic conventional surgery

surgery to remove the lung tumor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT00653250 - Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter